Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association.

Insel, Richard A ; Dunne, Jessica L ; Atkinson, Mark A ; Chiang, Jane L ; Dabelea, Dana ; Gottlieb, Peter A ; Greenbaum, Carla J ; Herold, Kevan C ; Krischer, Jeffrey P and Lernmark, Åke LU orcid , et al. (2015) In Diabetes Care 38(10). p.1964-1974
Abstract
Insights from prospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of β-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of β-cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials... (More)
Insights from prospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of β-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of β-cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio that will impact regulatory approval, reimbursement, and adoption of interventions in the early stages of type 1 diabetes to prevent symptomatic disease. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Diabetes Care
volume
38
issue
10
pages
1964 - 1974
publisher
American Diabetes Association
external identifiers
  • pmid:26404926
  • wos:000361840500036
  • scopus:84962430639
  • pmid:26404926
ISSN
1935-5548
DOI
10.2337/dc15-1419
language
English
LU publication?
yes
id
301f33d1-7709-4657-b5b9-b95e17b9565f (old id 8034996)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26404926?dopt=Abstract
date added to LUP
2016-04-01 11:14:58
date last changed
2025-04-04 14:20:22
@article{301f33d1-7709-4657-b5b9-b95e17b9565f,
  abstract     = {{Insights from prospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of β-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of β-cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio that will impact regulatory approval, reimbursement, and adoption of interventions in the early stages of type 1 diabetes to prevent symptomatic disease.}},
  author       = {{Insel, Richard A and Dunne, Jessica L and Atkinson, Mark A and Chiang, Jane L and Dabelea, Dana and Gottlieb, Peter A and Greenbaum, Carla J and Herold, Kevan C and Krischer, Jeffrey P and Lernmark, Åke and Ratner, Robert E and Rewers, Marian J and Schatz, Desmond A and Skyler, Jay S and Sosenko, Jay M and Ziegler, Anette-G}},
  issn         = {{1935-5548}},
  language     = {{eng}},
  number       = {{10}},
  pages        = {{1964--1974}},
  publisher    = {{American Diabetes Association}},
  series       = {{Diabetes Care}},
  title        = {{Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association.}},
  url          = {{http://dx.doi.org/10.2337/dc15-1419}},
  doi          = {{10.2337/dc15-1419}},
  volume       = {{38}},
  year         = {{2015}},
}